A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients
with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.